Abbott Laboratories vs Eli Lilly & Co.
ABT vs LLY — side-by-side comparison from reported financials. ABT leads 3, LLY leads 9 of 12 comparable metrics.
Abbott Laboratories
ABT · Healthcare
$99.78+1.31%Solid
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | ABT | LLY |
|---|---|---|
| Price | $99.78 | $1 177.20 |
| Market cap | $173B | $1.05T |
| Revenue (TTM) | $46.6B | $79.7B |
| Revenue growth | +0.5% | +31.7% |
| Net margin | 11.6% | 33.5% |
| Free cash flow | $7.82B | $18.2B |
| Net cash (debt) | ($957M) | ($35.2B) |
| 1-year price return | -25.2% | +37.6% |
| P/E | 31.8 | 41.6 |
| P/E vs own history (cheap-side %) | 44% | 88% |
| Dividend yield | 2.47% | 0.52% |
| Return on equity | 11% | 93% |
| Altman Z-score | 2.84 | 7.10 |
| CV checks passed | 10 of 11 | 11 of 11 |
| Employees | 115,000 | 50,000 |
Full résumé-style profiles: ABT CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.